Development, production and pharmacodynamics of human growth hormone.
Indian J Pediatr
;
1991 Sep-Oct; 58 Suppl 1(): 23-32
Article
in English
| IMSEAR
| ID: sea-80704
ABSTRACT
With the advent of recombinant DNA technology, it is possible to produce biosynthetic human growth hormone (B-hGH). Novo Nordisk A/S has developed a method for manufacturing B-hGH which is identical to the 22K fraction of pituitary human growth hormone (P-hGH), using a nonpathogenic strain of Escherichia coli as host. B-hGH has been investigated extensively in physical, chemical and biological studies and found to be identical to P-hGH. Pharmacological studies have revealed that B-hGH possesses the same pharmacokinetic and short-term metabolic profiles as P-hGH. Long term clinical studies have shown that B-hGH induces a significant increase in height velocity in children with growth hormone deficiency (GHD) and is characterized by a low antigenicity.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Rats
/
Time Factors
/
Recombinant Proteins
/
Humans
/
Growth Hormone
/
Human Growth Hormone
/
Drug Evaluation, Preclinical
/
Growth Disorders
/
Animals
Language:
English
Journal:
Indian J Pediatr
Year:
1991
Type:
Article
Similar
MEDLINE
...
LILACS
LIS